New hope for Hard-to-Treat breast cancer: drug duo targets rare mutation
NCT ID NCT07193394
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 37 times
Summary
This study tests a combination of two drugs, tucatinib and trastuzumab, in people with a specific type of advanced breast cancer that has a mutation in the HER3 gene. The cancer must be HER2-negative and has already been treated with at least two prior chemotherapies. The goal is to see if this drug pair can shrink tumors or stop them from growing for at least 24 weeks, offering a new treatment option when few exist.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER ( HER2 NEGATIVE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nîmes
NOT_YET_RECRUITINGNîmes, 30 029, France
Contact
Contact
-
Centre Antoine Lacassagne
NOT_YET_RECRUITINGNice, 06 189, France
Contact
Contact
-
Centre Eugène Marquis
NOT_YET_RECRUITINGRennes, 35 042, France
Contact
Contact
-
Chu Dupuytren- Limoges
NOT_YET_RECRUITINGLimoges, 87 042, France
Contact
Contact
-
Institut Curie_ Site Saint-Cloud
RECRUITINGSaint-Cloud, 92 210, France
Contact
Contact
-
Institut Paoli-Calmettes
NOT_YET_RECRUITINGMarseille, 13009, France
Contact
Contact
-
Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole Claudius Regaud
NOT_YET_RECRUITINGToulouse, 31 059, France
Contact
Contact
-
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITINGVandœuvre-lès-Nancy, 54 519, France
Contact
Contact
-
Polyclinique Bordeaux Nord Aquitaine
NOT_YET_RECRUITINGBordeaux, 33 300, France
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.